🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

The sexually transmitted infection are on the rise around the world, with data suggesting over 82 million infections per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Authorization

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

As per data published in a major medical journal, the new drug cured over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The study involved nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians on the front lines have shared optimism. The availability of a easy-to-administer therapy such as this is seen as a "critical tool" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.